Transcriptomic Analysis Identifies the Effect of Beta-Blocking Agents on a Molecular Pathway of Contraction in the Heart and Predicts Response to Therapy

Published

Journal Article (Review)

© 2016 The Authors Over the last decades, beta-blockers have been a key component of heart failure therapy. However, currently there is no method to identify patients who will benefit from beta-blocking therapy versus those who will be unresponsive or worsen. Furthermore, there is an unmet need to better understand molecular mechanisms through which heart failure therapies, such as beta-blockers, improve cardiac function, in order to design novel targeted therapies. Solving these issues is an important step towards personalized medicine. Here, we present a comprehensive transcriptomic analysis of molecular pathways that are affected by beta-blocking agents and a transcriptomic biomarker to predict therapy response.

Full Text

Duke Authors

Cited Authors

  • Heidecker, B; Kittleson, MM; Kasper, EK; Wittstein, IS; Champion, HC; Russell, SD; Baughman, KL; Hare, JM

Published Date

  • April 1, 2016

Published In

Volume / Issue

  • 1 / 3

Start / End Page

  • 107 - 121

International Standard Serial Number (ISSN)

  • 2452-302X

Digital Object Identifier (DOI)

  • 10.1016/j.jacbts.2016.02.001

Citation Source

  • Scopus